Category: Uncategorized

The Dales Report – Why Psychedelic Treatments Will Benefit Investors and Healthcare
Radius Research Interview – Algernon NeuroScience Initiates TBI Research Program with DMT
Proactive Investors CEO Interview – Algernon NeuroScience completes first dosing in Phase 1 clinical study of DMT
SR Times – “Drug Could Possibly Both Reduce Acute Damage of the Stroke” – How DMT Could be the Future of Stroke Treatment
Radius Research Interview – Algernon Pharmaceuticals (AGN) CEO Christopher J. Moreau – Ifendprodil Program Update Targeting Chronic Cough
Radius Research – Algernon Pharma (AGN) CEO Chris Moreau – AP-188 DMT Dimethyltryptamine Program Update
Benzinga – A Psychedelic Program For Treatment Of Stroke: New Clinical Trial Begins Dosing
Microdose: Microdosing DMT to Treat Stokes: Not as Trippy as it Sounds
Proactive Investors CEO Interview – Algernon NeuroScience Doses First Patient in Stroke Study
The Market Herald – Algernon Pharmaceuticals Announces Upcoming Phase 2b Chronic Cough Study of Ifenprodil

About Us

Get the skills, guidance, and resources you need to make a big difference in your contact center operations that can lead to a big difference

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.